Speculatively, HSP90 inhibitors may have an adjunctive role with immune checkpoint inhibitors given that in lung cancer TLR4 engagement promotes escape from immune tumour killing by increasing resistance to apoptosis and inducing immune suppressing cytokines [47]. Here, TLR4 is linked to lung cancer.